Tirzepatide as a GLP-1 agonist: the evidence behind the mechanism

Why calling tirzepatide a GLP-1 agonist is accurate but incomplete

GLP-1 (glucagon-like peptide-1) is a hormone released from the gut after eating. It signals to the brain that you are full, slows the rate at which the stomach empties, and helps regulate blood sugar. Medicines that mimic this signal, known as GLP-1 receptor agonists, have been used to treat type 2 diabetes for many years and more recently for weight management.

Tirzepatide does activate the GLP-1 receptor, so is tirzepatide a GLP-1 agonist is a fair question with a yes answer. The fuller picture, though, is that it also activates the GIP receptor (glucose-dependent insulinotropic polypeptide) a second gut hormone involved in fat storage, appetite and metabolic rate. Because it targets both pathways simultaneously, tirzepatide is described more precisely as a dual GIP and GLP-1 agonist, and sometimes as a twincretin. This distinction matters clinically: the combination appears to produce greater appetite suppression and weight loss than GLP-1 activity alone, at least in the trial data published so far.

The NHS medicines page on tirzepatide describes both mechanisms in plain language and is a reliable starting point for anyone wanting to understand what the medicine does before speaking to a clinician.

What SURMOUNT-1 and the NICE appraisal tell us

The evidence base for tirzepatide as a weight-management medicine rests primarily on the SURMOUNT programme. SURMOUNT-1 randomised 2,539 adults with obesity but without type 2 diabetes and followed them for 72 weeks. At the 15mg dose, average body-weight reduction was around 20–21%, a result published in the New England Journal of Medicine in 2022. To put that in context: participants who had been unable to lose meaningful weight through diet and activity alone were, on average, losing roughly a fifth of their body weight over a year and a half of treatment.

NICE reviewed this evidence formally, publishing its appraisal as TA1026 in December 2024 (updated September 2025). The committee found tirzepatide suitable for NHS use in adults with a BMI of 35 or above plus at least one qualifying weight-related condition, high blood pressure, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, those thresholds are reduced by 2.5 kg/m².

Head-to-head data from SURMOUNT-5, published in the New England Journal of Medicine in 2025, showed tirzepatide producing greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. That is worth noting because semaglutide already showed impressive results in its own trials. The comparison is indirect on some measures, and individual responses vary, but the direction of evidence is consistent. For a broader look at how tirzepatide compares with other options, the tirzepatide and GLP-1 overview covers this in more detail.

Practical realities: dosing schedule and what the body experiences

Tirzepatide is injected once a week using a pre-filled KwikPen. Treatment begins at 2.5mg, a starting dose chosen for tolerability, not therapeutic effect. The prescriber typically increases the dose in steps every four weeks, working through 5mg, 7.5mg, 10mg, 12.5mg and up to 15mg. The pace of that titration depends on how each person tolerates the medicine, which is why clinical oversight throughout is not just a regulatory requirement but a practical necessity.

Because tirzepatide slows gastric emptying, the most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, acid reflux and burping tend to cluster around dose increases and often ease within a week or two as the body adjusts. Fatigue, headache and mild dizziness are also reported. These are not rare; most people starting this medicine notice something. Knowing that in advance (rather than being caught off guard mid-week) makes the difference between stopping unnecessarily and managing it sensibly.

One point worth flagging to anyone researching how tirzepatide fits into the wider GLP-2 and incretin landscape more broadly: tirzepatide's GIP activity may also affect how oral contraceptives are absorbed during the first four weeks of treatment and after each dose increase. NHS guidance recommends adding a non-oral method of contraception during those windows. It is the sort of detail a prescriber will raise at assessment, but worth knowing about before you start.

Private treatment and what a clinical assessment involves

Most people asking about tirzepatide as a GLP-1 agonist are, reasonably, wondering whether it might be right for them. NHS access is currently limited to specific clinical criteria and phased cohorts, meaning many people who could benefit are waiting or do not qualify yet. Private treatment through a GPhC-registered online pharmacy is the regulated alternative.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber. A real clinician reviews your answers the same day, not software, not a queue that takes three days. Identity is verified with photo ID, and weight is confirmed on video. Treatment is dispatched once approved, with free next-working-day delivery by DPD. Some people place their order in the morning and have their consultation reviewed before the school-run deadline of 12pm. For a sense of what treatment costs and what is included, the Mounjaro price comparison page sets out the context honestly, including what headline prices from other providers sometimes leave out.

If you would like to find out whether tirzepatide is clinically suitable for you, our prescribers are the right people to ask, and you can read more about how tirzepatide works as a GIP agonist before starting your assessment. You can start your free consultation and have your answers reviewed the same day.